Search PubMed⌕ Search

Biomedical subjects

R Punnonen

Publications and source records attributed to R Punnonen.

At least 199 records · Page 11Linked to original sources
PubMed1978

Serum oestrone, oestradiol and oestriol concentrations during oral oestradiol valerate and oestriol succinate therapy in ovariectomized women.

Serum oestrone, oestradiol and oestriol concentrations were investigated during oral treatment with oestradiol valerate and oestriol succinate in ovariectomized women. The dosages used were 1 mg oestradiol valerate in the morning and 2 mg oestriol succinate in the evening of the first day and 2 mg oestradiol valerate in the morning of the second day of treatment. The other group of patients received the same therapy in reverse order. The variation in the serum oestrone and oestradiol concentrations with a daily dose of 1 or 2 mg of oestradiol valerate were considerable. 2 mg oestriol succinate caused a fairly small elevation of serum oestriol concentration. In both treatment groups the quotient E3/(E2 + E1) was similar to that found at the 6-7th day and in the middle of the normal menstrual cycle, the quotient E1/(E2 + E3) was somewhat higher than during normal cycle.

Castration↗
PubMed1977

The relationship between serum oestradiol levels and serum triglyceride, cholesterol and phospholipid levels in normal human pregnancy.

Blood samples were obtained for serum lipid and oestradiol measurement from 365 women between 7 to 41 weeks of normal pregnancy. In an additional 21 women serum lipid and oestradiol were measured at 20 to 23 weeks gestation and again at 30 to 33 weeks. Significant correlations were noted between changes in the serum triglyceride and oestradiol levels (P less than 0.001) and between changes in serum cholesterol and oestradiol levels (P less than 0.05). The changes in phospholipid and oestradiol levels were not significantly correlated (P less than 0.1). The serum triglyceride level (mean +/- SEM) was highest at 37 weeks gestation (3.8 +/- 0.3 mmol/l), an increase of 400 per cent over the level at 7 weeks. The serum phospholipid level increased by 108 per cent to its highest levels (5.0 +/- 0.2 mmol/l) at 38 weeks and the cholesterol level increased by 93 per cent to its peak (8.7 +/- 0.3 mmol/l) at 38 weeks.

Cholesterol↗
PubMed1977

The effect of various doses of oral oestradiolvalerate and oestriolsuccinate on urine calcium/creatinine, serum FSH and endometrium in castrated women.

The effects of various doses recommended for clinical use of oestradiolvalerate and oestriolsuccinate on urine calcium/creatinine, serum FSH and endometrium were investigated in two castrated women. Oestrogen treatments were given in 6-week periods separated by 2 weeks without treatment. After various oestrogen treatments, serum FSH generally decreased clearly and urine calcium/creatinine slightly. The proliferative effect on endometrium was investigated histologically. In no period was a hyperplastic endometrium found.

Adult↗
PubMed1977

Carpal Tunnel syndrome in ovariectomized women.

Electrophysiological parameters were studied in 32 gynecological patients before and after major gynecological surgery. No changes in maximal nerve conduction velocity or simple reaction time could be found after either hysterectomy or ovariectomy. Of the 20 ovariectomized patients, 3 developed subjective symptoms and electrophysiological signs of the carpal tunnel syndrome within a few months after surgery. Thus the carpal tunnel syndrome, which is common in women of menopausal age, seems to be precipitated also by iatrogenic menopause. The present findings indicate that ovarian relaxin overproduction cannot be the basis of the carpal tunnel syndrome, but they are consistent with the view that the syndrome is a sign of hypothalamichypophyseal overactivity or imbalance.

Action Potentials↗
PubMed1977

The effect of long-term oral oestriol succinate therapy on the skin of castrated women.

The effect of three years oestriol succinate therapy (2 mg/day) on the skin was studied in 20 castrated women whose average age was 48 years. A control group whose average age was also 48 years, consisted of 7 patients who did not receive any treatment after castration. There was no significant reduction in epidermal thickness during the three year course of oestriol succinate therapy. On the other hand the significant thinning of the epidermis in the control group was observed three years after oophorectomy. The difference between the 3H-thymidine labelling indices in oestrogen and control groups was not significant three years after castration.

Administration, Oral↗
PubMed1976

Complications following radiotherapy in gynaecological carcinoma: comparison between X-ray and megavoltage therapy.

The use of megavoltage therapy has in some investigations been shown to be associated with improvement in the prognosis of gynaecological carcinoma. Our purpose was to clarify whether the character or number of complications has changed with the increased effectiveness of treatment. During the years 1967-1970 a total of 449 cases of gynaecological carcinoma (cervical, endometrial, ovarian) were treated at the Department of Obstetrics and Gynaecology and the Department of Radiation Therapy, Turku University; tele-Cobalt was used for external radiation. The comparison period was the years 1963-1965 when 289 patients were treated, the external radiation then in use being X-ray therapy. Intracavitary radiation was given in both groups using the modified Stockholm method for cervical carcinoma and the Heyman method for endometrial carcinoma. Operative activity was about the same in both periods. Patients with cervical carcinoma treated with tele-Cobalt appeared to have a higher frequency of severe intestinal complications (12.4%) than patients receiving X-ray therapy (6.0%); the difference was not, however, statistically significant. The same is true concerning the treatment groups of ovarian cancer (4.8% and 0% respectively) and those of endometrial carcinoma (5.2% and 1.2%). However, if all the patients as a group are considered and also those with urological complications, the difference was significant (p less than 0.05), the frequency of complications being 7.6% for patients treated with tele-Cobalt and 4.2% for those treated with X-ray therapy. One must take into account that in all cases the most difficult complications were seen in patients treated with tele-Cobalt, where surgical treatment was necessary in 29%.

Adult↗
PubMed1976

Effect of castration and long-term oral oestrogen therapy with oestriol succinate on serum lipids.

The effects of continuous oestriol succinate therapy (2 mg/day) of three years' duration on serum cholesterol, triglycerides and phospholipids were investigated on 50 women with a mean age of 48 years. In addition, the effects of castration only were investigated in 10 women with a similar mean age. One month after castration the serum cholesterol, triglyceride and phospholipid levels were significantly raised (p less than 0.05). During oestriol succinate therapy the cholesterol level tended to decrease. In the control group without hormone therapy, the cholesterol level showed a tendency to rise during the three years. The serum triglyceride and phospholipid levels remained almost unchanged during the oestriol succinate therapy and differed not from corresponding values of the control group.

Administration, Oral↗
PubMed1975

Studies on the effect of 17alpha-ethinyl-6-estrene-5alpha, 7beta-diol on menstrual cycle and plasma and urinary hormones in normal women.

Pharmacological tests on rats and dogs showed that a novel steroid substance, ORG OI-65 (code name for 17alpha-ethinyl-6-estrene-5alpha, 7beta-diol) has both progestational and estrogenic properties. The effect of this substance on menstrual cycle was studied on 13 healthy fertile women, who received 2 mg of ORG OI-65 daily for 20 consecutive days from the 5th day of cycle. The following parameters were studied during pretreatment and treatment cycles: bleeding pattern, plasma progesterone, urinary excretion of FSH, LH and estrone, vaginal cytology, cervical mucus, endometrium biopsy and basal body temperature. Treatment with ORG OI-65 did not change the bleeding pattern or inhibit ovulation: all 12 cases with ovulatory pretreatment cycles showed evidence of ovulation--timely or delayed--also during ORG OI-65 treatment. The vaginal cytology and cervical mucus remained almost unaffected by the treatment. No serious side-effects were found. The authors conclude that ORG OI-65 2 mg daily is not effective enough for oral contraception.

17-Ketosteroids↗